Abivax SA announced that four scientific abstracts on its lead drug candidate, obefazimod, for the treatment of moderately to severely active ulcerative colitis (UC) and in a preclinical model on colon cancer, will be presented at Digestive Disease Week (DDW) as part of scientific exchange, taking place May 18-21, 2024, in Washington D.C., U.S.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.7 EUR | +1.28% |
|
+1.93% | +29.33% |
May. 20 | BTIG Initiates Abivax at Buy Rating With $43 Price Target | MT |
May. 08 | Abivax: four abstracts to be presented on obefazimod | CF |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.33% | 871M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- ABVX Stock
- News Abivax
- Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024